Dataset Information

Comprehensive selectivity profile of PARP inhibitors using a target-centric bead matrix

ABSTRACT: Explore selectivity of several PARP inhibitors against proteins of the PARP family.

INSTRUMENT(S): Orbitrap Fusion Lumos, Q Exactive HF-X, Orbitrap Exploris 480, Q Exactive HF

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Mda-mb-231 Cell, Cell Line Cell

SUBMITTER: Maria Faelth Savitski

LAB HEAD: Marcus Bantscheff

PROVIDER: PXD044329 | Pride | 2025-05-06

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	03281_F1_R1_P0268458B01_TMT10.raw.gz	Raw
	03281_F1_R1_P0268458B02_TMT10.raw.gz	Raw
	03281_F1_R1_P0268458B03_TMT10.raw.gz	Raw
	03281_F1_R1_P0268458B04_TMT10.raw.gz	Raw
	03281_F1_R1_P0268458B05_TMT10.raw.gz	Raw

Items per page:

1 - 5 of 106

Publications

Synergistic Effects of PARP Inhibition and Cholesterol Biosynthesis Pathway Modulation.

Rutkowska Anna A Eberl H Christian HC Werner Thilo T Hennrich Marco L ML Sévin Daniel C DC Petretich Massimo M Reddington James P JP Pocha Shirin S Gade Stephan S Martinez-Segura Amalia A Dvornikov Dmytro D Karpiak Joel J Sweetman Gavain M A GMA Fufezan Christian C Duempelfeld Birgit B Braun Florian F Schofield Christopher C Keles Hakan H Alvarado David D Wang Zhuo Z Jansson Keith H KH Faelth-Savitski Maria M Curry Edward E Remlinger Katja K Stronach Euan A EA Feng Bin B Sharma Geeta G Coleman Kevin K Grandi Paola P Bantscheff Marcus M Bergamini Giovanna G

Cancer research communications 20240901 9

An in-depth multiomic molecular characterization of PARP inhibitors revealed a distinct poly-pharmacology of niraparib (Zejula) mediated by its interaction with lanosterol synthase (LSS), which is not observed with other PARP inhibitors. Niraparib, in a similar way to the LSS inhibitor Ro-48-8071, induced activation of the 24,25-epoxysterol shunt pathway, which is a regulatory signaling branch of the cholesterol biosynthesis pathway. Interestingly, the combination of an LSS inhibitor with a PARP ...[more]

PMID: 39028932

Similar Datasets

Project description:In patients with advanced colorectal cancer, leucovorin, fluorouracil, and irinotecan (FOLFIRI) is considered as one of the reference first-line treatments. However, only about half of treated patients respond to this regimen, and there is no clinically useful marker that predicts response. A major clinical challenge is to identify the subset of patients who could benefit from this chemotherapy. We aimed to identify a gene expression profile in primary colon cancer tissue that could predict chemotherapy response. Patients and Methods:- Tumor colon samples from 21 patients with advanced colorectal cancer were analyzed for gene expression profiling using Human Genome GeneChip arrays U133. At the end of the first-line treatment, the best observed response, according to WHO criteria, was used to define the responders and nonresponders. Discriminatory genes were first selected by the significance analysis of microarrays algorithm and the area under the receiver operating characteristic curve. A predictor classifier was then constructed using support vector machines. Finally, leave-one-out cross validation was used to estimate the performance and the accuracy of the output class prediction rule. Results:- We determined a set of 14 predictor genes of response to FOLFIRI. Nine of nine responders (100% specificity) and 11 of 12 nonresponders (92% sensitivity) were classified correctly, for an overall accuracy of 95%. Conclusion:- After validation in an independent cohort of patients, our gene signature could be used as a decision tool to assist oncologists in selecting colorectal cancer patients who could benefit from FOLFIRI chemotherapy, both in the adjuvant and the first-line metastatic setting. All tissue samples were maintained at −180°C (liquid nitrogen) until RNA extraction and were weighed before homogenization. Tissue samples were then disrupted directly into a lysis buffer using Mixer Mill MM 300 (Qiagen, Valencia, CA). Total RNA was isolated from tissue lysates using the RNeasy Mini Kit (Qiagen), and additional DNAse digestion was performed on all samples during the extraction process (RNase-Free DNase Set Protocol for DNase treatment on RNeasy Mini Spin Columns; Qiagen). After each extraction, a small fraction of the total RNA preparation was taken to determine the quality of the sample and the yield of total RNA. Controls analyses were performed by UV spectroscopy and analysis of total RNA profile using the Agilent RNA 6000 Nano LabChip Kit with the Agilent 2100 Bioanalyser (Agilent Technologies, Palo Alto, CA) to determine RNA purity, quantity, and integrity.